Ultragenyx and Kyowa Kirin Announce Burosumab Receives Positive CHMP Opinion for the Treatment of X-Linked Hypophosphatemia in Children

December 15, 2017

Responsive image

TOKYO, LONDON, and NOVATO, California, December 15, 2017 /PRNewswire/ —
If approved, burosumab would be the first targeted disease-modifying treatment for XLH  
Kyowa Hakko Kirin Co., Ltd. (Kyowa Hakko Kirin), Kyowa Kirin International PLC (Kyowa Kirin International) and Ultrage…

Category: Precious Metals